Depression as a microglial disease

Area of Science:

• Neuroscience
• Immunology
• Psychiatry

Background:

• The precise biological mechanisms of depression remain elusive, hindering novel antidepressant development.
• Emerging research links depression to impaired microglial function, affecting neuroplasticity and neurogenesis.
• Microglial dysfunction can arise from inflammation or senescence, impacting brain health.

Purpose of the Study:

• To explore the role of microglia in the pathophysiology of depression.
• To propose a novel perspective of depression as a microglial disease (microgliopathy).
• To suggest a personalized treatment approach for depression based on microglial status.

Main Methods:

• Review of recent scientific literature on microglia and depression.
• Analysis of conditions leading to microglial impairment (inflammation, senescence).
• Correlation of microglial status with neuroplasticity and neurogenesis deficits.

Main Results:

• Microglial impairment, due to inflammation or aging, is associated with depression.
• Altered microglia can disrupt neuroplasticity and neurogenesis, contributing to depressive symptoms.
• Certain depression forms may be classified as microgliopathies.

Conclusions:

• Depression can be viewed as a microglial disease, or microgliopathy.
• Personalized medicine targeting microglial function (inhibition or stimulation) is a promising avenue for depression treatment.
• Understanding microglial status is key to developing effective, individualized antidepressant strategies.